In this study, we administered an ARB (candesartan: only sartan which can use for chronic heart failure patients in Japan) to hypertensive patients with type 2 diabetes mellitus and evaluated whether there was improvement in the following inflammatory parameters: high molecular weight adiponectin (HMW-ADN), plasminogen activator inhibitor-1 (PAI-1), highly sensitive C-reactive protein (Hs-CRP), vascular cell adhesion molecule-1 (VCAM-1) and urinary 8-hydroxydeoxyguanosine (U-8-OHdG). Here, VCAM1 is linked to diabetes mellitus.